DALLAS – BeaconEquity.com announces the publication of ‘Momenta Pharmaceuticals, Inc. (MNTA) Sets Priority on M-Enoxaparin Launch’
Investors can view all of the investment articles for free by visiting:
http://www.beaconequity.com/ - Click on News and Commentary
Momenta Pharmaceuticals, Inc. (MNTA) Sets Priority on M-Enoxaparin Launch
The US biotechnology industry includes about 1,000 companies, with combined annual revenue close to $50 billion. Rapid advances in biotechnology marks the 2000s as the Biotechnology Era, with many aspects of life revolutionized during this period. Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company, specializes in the structural analysis of complex mixture drugs. The Company applies its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs.
The products of Momenta Pharmaceuticals include M-Enoxaparin, a technology-enabled generic version of Lovenox that is used to prevent and treat deep vein thrombosis and to support the treatment of acute coronary syndromes; and M356, a technology-enabled generic version of Copaxone, which is used for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis.
Momenta Pharmaceuticals, Inc. recently reported its financial results for the fourth quarter and year ended December 31, 2007. For the fourth quarter of 2007, revenue was $10.0 million, compared to $4.0 million for the same period last year; while for the year ended December 31, 2007, revenue was $21.6 million, compared to $16.0 million for 2006. The increase in revenue in both periods was a result of increased reimbursable expenses associated with preparing for the potential commercial launch of M-Enoxaparin in the U.S and amortization of the equity premium related to the 2006 collaboration agreement with Sandoz A.G.
To read the entire article visit http://www.beaconequity.com/ – Click on News and Commentary
Join the fastest growing investor community at:
http://www.stockhideout.com
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.beaconequity.com/
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
